Anesthesiology · 2014 · 36 citations · 44 references
MedicineImmunologyPathologyImmunopathologyInnate ImmunitySepsisHepatic PathophysiologyHepcidin RegulationIron HomeostasisIron MetabolismLiver DiseaseSepsis PathophysiologyHepatic Iron AccumulationHepatic Iron RegulationHepcidin DysregulationHepcidin ExpressionHepcidin Transcriptional ControlHepcidin-mediated Iron ControlLiver Hepcidin RegulationSystemic Iron Homeostasis
BACKGROUND: Hepcidin is a master regulator of iron metabolism primarily produced by the liver. Markedly increased hepcidin levels have been observed in septic individuals, while decreased hepatic hepcidin expression has been demonstrated in liver diseases that tend to develop into sepsis. However, the role of liver hepcidin in sepsis remains unknown. METHODS: Mouse hepatic hepcidin expression was silenced using adenovirus-mediated hepcidin-specific short hairpin RNA injected via the tail vein. Sepsis was induced by cecal ligation and puncture, and the outcome (n = 23 for hepcidin knockdown mice, n = 15 for controls) and pathogenic changes (n = 5) related to sepsis were evaluated. The impact of alteration of iron status on the survival rate of hepatic hepcidin knockdown mice (n = 18 to 19) was also investigated. RESULTS: Disruption of liver hepcidin expression increased serum iron level (537.8 ± 28.1 μg/dl [mean ± SD] vs. 235.9 ± 62.2 μg/dl; P < 0.05) and reduced iron content in the spleen macrophages at the steady state. Hepatic hepcidin knockdown mice not only showed increased 7-day mortality (73.9% vs. 46.7%; P < 0.05), but also had exacerbated organ damage and oxidative stress, as well as compromised host inflammatory responses and bacterial clearance at 24 h after polymicrobial sepsis. Treating the hepatic hepcidin knockdown mice with low-iron diet plus iron chelation decreased systemic iron content (serum level: 324.0 ± 67.4 μg/dl vs. 517.4 ± 13.4 μg/dl; P < 0.05) and rescued the mice from lethal sepsis (7-day survival: 36.8% vs. 83.3%; P < 0.01). CONCLUSIONS: Hepatic hepcidin plays an important role in sepsis through regulation of iron metabolism. The findings may have potential therapeutic implications for liver diseases in which hepcidin expression is decreased.
44
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Elizabeta Nemeth, Erika V. Valore, Mary Territo et al. · Blood · 2003 · 1.4K citations · Full text
Medicine, Hematology, Immunology +14
LEAP‐1, a novel highly disulfide‐bonded human peptide, exhibits antimicrobial activity
Alexander Krause, Susanne Neitz, Hans‐Jürgen Mägert et al. · FEBS Letters · 2000 · 1.3K citations · Full text
Gaël Nicolas, Myriam Bennoun, Isabelle Devaux et al. · Proceedings of the National Academy of Sciences · 2001 · 1.2K citations · Full text